Mekong Malaria Programme

 

Vision

 

 

The Mekong Malaria Programme’s overarching contribution alongside with Government and Non-Government Partners is to improve the health status of the population with special focus on malaria control and containment of malaria drug resistance in the Greater Mekong Subregion

 

Background

 

 

The Mekong Malaria Programme (MMP), originally launched in Ho Chi Minh City in 1999 as the Mekong Roll Back Malaria Initiative, brought together all national programs and partners working on malaria in the Greater Mekong Subregion (GMS). It both reinvigorated existing strategic projects in the Mekong region as well as initiated new ones. The multi-partners’ programme, supported mainly with USAID funds, paid particular attention to the following technical areas: (1) monitoring therapeutic efficacy of anti-malarial drugs used in the Mekong region to update national drug policies and implement cross-country strategies to address multi-drug resistance, (2) monitoring quality, access and use of antimalarials available in the field, (3) increasing capacity of national staff to select, plan and monitor malaria control activities, (4) setting up regular exchange forums and technical consultations to identify, share and disseminate best practices in malaria control including cross border activity projects throughout the GMS, (5) strengthening Mekong malaria surveillance, and (6) setting up and monitoring the malaria research agenda.

 

As a result, more partners became actively engaged in malaria control and were supporting national authorities to successfully reach their national targets. The Global Fund to Fight AIDS, Tuberculosis and Malaria, since it started operating in 2002, has awarded more than USD 500 million in malaria control or elimination to Mekong countries. 

 

Goal

 

 

The Mekong Malaria Programme aims to facilitate the implementation and monitoring of a comprehensive MMP Malaria Strategy endorsed by national authorities and stakeholders to address common Mekong challenges in order to consolidate existing results and further impact on malaria morbidity and mortality. 

 

Back

 

| | | | | |